Stay updated on Gantenerumab in Early Alzheimer's Disease Clinical Trial
Sign up to get notified when there's something new on the Gantenerumab in Early Alzheimer's Disease Clinical Trial page.

Latest updates to the Gantenerumab in Early Alzheimer's Disease Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov record for the Phase 3 gantenerumab study in early Alzheimer’s disease is displayed, including its terminated status, study design, eligibility criteria, locations, outcome measures, results, and study documents.SummaryDifference100%

- Check12 days agoChange DetectedThe footer’s displayed site revision changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide notice about NIH’s transition from “Artificial Intelligence” to “Super Intelligence” appears above the error page, and the site revision identifier is updated.SummaryDifference1%

- Check40 days agoChange DetectedThe footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe page now displays a 403 Forbidden error for the study record instead of the usual content, indicating that access to the record is blocked.SummaryDifference18%

- Check61 days agoChange DetectedA new study location San Martin de Porres, Peru, 15102 was added and the San Martín de Porres entry was removed. The page revision was updated from v3.6.6 to v3.7.0.SummaryDifference0.0%

Stay in the know with updates to Gantenerumab in Early Alzheimer's Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gantenerumab in Early Alzheimer's Disease Clinical Trial page.